•
SR
SRZN
Surrozen, Inc. Common
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
154.11M
Volume
58.46K
52W High
$24.94
52W Low
$5.90
Open
$19.38
Prev Close
$17.98
Day Range
18.74 - 20.46
About Surrozen, Inc. Common
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Latest News
Surrozen Reports Q2 Profit on Gains
The Motley Fool•Aug 8
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
GlobeNewswire Inc.•Jun 12
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
GlobeNewswire Inc.•Jun 10
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
GlobeNewswire Inc.•Jun 4
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire Inc.•May 9
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
GlobeNewswire Inc.•Apr 3
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.•Apr 1
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
GlobeNewswire Inc.•Apr 1